Limited and its subsidiaries for the first quarter ended 31 March 2020 represented a loss attributable to owners of the Company of Baht 18.29 million. Compared to the same period of 2019 showed a loss of
August 11, 2020 Re : Management Discussion and Analysis for Q2/2020 To : Director and Manager of the Stock Exchange of Thailand Revenue from sales and rendering of services L&E’s consolidated revenue
MATI 10/2563 August 14, 2020 Subject Consolidated Financial Report for the six-month period which ended at June 30, 2020 To Director and Manager, The Stock Exchange of Thailand Six-month period
1 Ref: CK-20-0000-AFD(AC)-L-0042 August 14, 2020 Subject: Clarification on Operating Result and Financial Position for the six-month period ended June 30, 2020 Attention: President The Stock Exchange
and Analysis Yearly Ending 31 Dec 2019 13/11/2019 17:09 Management Discussion and Analysis Quarter 3 Ending 30 Sep 2019 13/08/2019 19:43 Management Discussion and Analysis for the Performance for Six
PUBLIC COMPANY LIMITED Disclosure Business News ( 2 record(s) found) Date Time Heading Link 13/08/2019 08:04 Interim Dividend Payment for the year 2019 13/08/2019 08:04 Connected Transaction Remark: Data
Convening of 2021 AGM (Amended) 08/03/2021 22:12 Resolutions of the Board of Directors' Meeting regarding the schedule and agenda items for the 2021 AGM 08/03/2021 22:12 Resolutions of the Board of Directors
year to THB 4.6 billion for the first quarter of 2020 from THB 5.1 billion for the first quarter 2019. Sales Revenue in USD terms decreased 9% to USD 147m for Q1 2020 from USD 162m in Q1 2019. Operating
August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries
Our Ref: No.V. 029 /2020 August 14,2020 Subject : Explanation for operation of second quarter of year 2020 Attn : Managing Director The Stock Exchange of Thailand Enclosed please find the financial